Sage Journals: Discover world-class research

Abstract

Introduction

No clear guidelines exist for unfractionated heparin (UFH) monitoring in adult patients on veno-arterial extracorporeal life support (VA-ECLS) for refractory cardiogenic shock. In this study, we sought to compare outcomes between anti-factor Xa (FXa) and activated partial thromboplastin time (aPTT) strategies for UFH monitoring during VA-ECLS.

Methods

This is a single-center, retrospective review of VA-ECLS patients who received UFH in the cardiothoracic intensive care unit between July 2019 and November 2023. Standard protocol for UFH titration was aPTT goal of 45-60 sec (n = 52) before September 2021, then transitioned to FXa goal of 0.1-0.2 U/mL (n = 50) thereafter. Inverse probability of treatment weighting was used to balance baseline differences between cohorts.

Results

In adjusted analyses, 89.3% of FXa patients and 76.0% of aPTT patients achieved goal range for their respective assay. Total UFH duration (4.0 vs 4.0 days, p = .239) and maximum weight-adjusted UFH dose (9.3 vs 9.4 U/hr/kg, p = .823) remained comparable between adjusted FXa and aPTT cohorts. Moreover, in-hospital mortality (50.3% vs 33.9%, p = .133), major bleeding events (20.6% vs 11.2%, p = .292), and thromboembolic events (30.1% vs 30.1%, p = .998) were not significantly different. Extracorporeal circuit thrombosis and cannula site bleeding were the most frequent events in both groups. Multivariate logistic regression found the FXa strategy was not a significant risk factor for the composite outcome of major bleeding or thromboembolism (OR [95% CI]: 1.539 [0.575, 4.116], p = .393).

Conclusions

In adult VA-ECLS patients at our institution, bleeding and thromboembolic complications occurred at a similar rate regardless of which UFH monitoring strategy was utilized. Further studies in larger and more institutionally diverse cohorts are warranted.

Keywords

VA-ECMO anticoagulation anti-factor Xa mechanical circulatory support heart failure

Get full access to this article

View all access options for this article.

References

Karagiannidis

Brodie

Strassmann

, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med 2016; 42: 889–896. DOI: 10.1007/s00134-016-4273-z.

Doyle

Hunt

. Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components. Front Med 2018; 5: 352. DOI: 10.3389/fmed.2018.00352.

Rehder

Turner

Bonadonna

, et al. Technological advances in extracorporeal membrane oxygenation for respiratory failure. Expert Rev Respir Med 2012; 6: 377–384. DOI: 10.1586/ers.12.31.

Oliver

WC.

Anticoagulation and coagulation management for ECMO. Semin CardioThorac Vasc Anesth 2009; 13: 154–175. DOI: 10.1177/1089253209347384.

Onishi

St Ange

Dordick

, et al. Heparin and anticoagulation. Frontiers in Bioscience - Landmark 2016; 21: 1372–1392. DOI: 10.2741/4462.

Vandiver

Vondracek

. Antifactor xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012; 32: 546–558. DOI: 10.1002/j.1875-9114.2011.01049.x.

Amiral

Dunois

. Optimization of heparin monitoring with anti-FXa assays and the impact of dextran sulfate for measuring all drug activity. Biomedicines 2021; 9: 700. DOI: 10.3390/biomedicines9060700.

Francis

Groce

. Challenges in variation and responsiveness of unfractionated heparin. Pharmacotherapy 2004, 24, pp. 108–119. DOI: 10.1592/phco.24.12.108s.36114.

Rosenberg

Zumberg

Taylor

, et al. The use of anti-xa assay to monitor intravenous unfractionated heparin therapy. J Pharm Pract 2010; 23: 210–216. DOI: 10.1177/0897190010362172.

10.

Scott

Rotar

Dahl

, et al. Discordance among assays for monitoring? Anticoagulation during extracorporeal life support. Perfusion 2023; 38: 1714–1721. DOI: 10.1177/02676591221129741.

11.

Aubron

Chapalain

Bailey

, et al. Anti-factor-Xa and activated partial thromboplastin time Concordance and outcomes in adults undergoing extracorporeal membrane oxygenation: a secondary analysis of the Pilot low-dose heparin in critically ill patients undergoing extracorporeal membrane oxygenation Randomized trial. Crit Care Explor 2023; 5: 999. DOI: 10.1097/CCE.0000000000000999.

12.

Moussa

Soquet

Lamer

, et al. Evaluation of anti-activated factor x activity and activated partial thromboplastin time relations and their association with bleeding and thrombosis during veno-arterial ecmo support: a retrospective study. J Clin Med 2021; 10: 2158. DOI: 10.3390/jcm10102158.

13.

McMichael

ABV

Ryerson

Ratano

, et al. 2021 ELSO adult and pediatric anticoagulation guidelines. Am Soc Artif Intern Organs J 2022; 68: 303–310. DOI: 10.1097/MAT.0000000000001652.

14.

Liveris

Bello

Friedmann

, et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2014; 15: 72–29. DOI: 10.1097/PCC.0000000000000028.

15.

O’Meara

Alten

Goldberg

, et al. Anti-Xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation. Am Soc Artif Intern Organs J 2015; 61: 339–344. DOI: 10.1097/MAT.0000000000000204.

16.

Khaja

Bilen

Lukner

, et al. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol 2010; 134: 950–954. DOI: 10.1309/AJCPGVD62LKKVDLH.

17.

Ignjatovic

Mertyn

Monagle

. The coagulation system in children: Developmental and pathophysiological considerations. Seminars in Thrombosis and Hemostasis 2011, 37, pp. 723–729. DOI: 10.1055/s-0031-1297162.

18.

Kulig

Schomer

Black

, et al. Activated partial thromboplastin time versus anti-factor xa monitoring of heparin anticoagulation in adult Venoarterial extracorporeal membrane oxygenation patients. Am Soc Artif Intern Organs J 2021; 67: 411–415. DOI: 10.1097/MAT.0000000000001246.

19.

Arnouk

Altshuler

Lewis

, et al. Evaluation of anti-xa and activated partial thromboplastin time monitoring of heparin in adult patients receiving extracorporeal membrane oxygenation support. Am Soc Artif Intern Organs J 2020; 66: 300–306. DOI: 10.1097/MAT.0000000000001004.

20.

Silber

Rosenbaum

Trudeau

, et al. Multivariate matching and bias reduction in the surgical outcomes study. Med Care 2001; 39: 1048–1064. DOI: 10.1097/00005650-200110000-00003.

21.

Willems

Roeleveld

Labarinas

, et al. Anti-Xa versus time-guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta-analysis. Perfusion 2021; 36: 501–512. DOI: 10.1177/0267659120952982.

22.

Nunez

Gosling

O’Gara

, et al. Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis. Intensive Care Med 2022; 48: 213–224. DOI: 10.1007/s00134-021-06593-x.

23.

Bellomy

Engoren

Martin

, et al. The attributable mortality of postoperative bleeding exceeds the attributable mortality of postoperative venous thromboembolism. Anesth Analg 2021; 132: 82–88. DOI: 10.1213/ANE.0000000000004989.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.28 MB

Unfractionated heparin monitoring by anti-factor Xa versus activated partial thromboplastin time strategies during venoarterial extracorporeal life support